Search Page

1

Cite

Share

Gene promoter hypermethylation in mouse lung tumors.

Vuillemenot BR, Hutt JA, Belinsky SA. Vuillemenot BR, et al. Mol Cancer Res. 2006 Apr;4(4):267-73. doi: 10.1158/1541-7786.MCR-05-0218. Mol Cancer Res. 2006. PMID: 16603640

Cite

Share

2

Cite

Share

Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways.

Hutt JA, Vuillemenot BR, Barr EB, Grimes MJ, Hahn FF, Hobbs CH, March TH, Gigliotti AP, Seilkop SK, Finch GL, Mauderly JL, Belinsky SA. Hutt JA, et al. Among authors: vuillemenot br. Carcinogenesis. 2005 Nov;26(11):1999-2009. doi: 10.1093/carcin/bgi150. Epub 2005 Jun 8. Carcinogenesis. 2005. PMID: 15944214

Cite

Share

3

Cite

Share

Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis.

Vuillemenot BR, Pulling LC, Palmisano WA, Hutt JA, Belinsky SA. Vuillemenot BR, et al. Carcinogenesis. 2004 Apr;25(4):623-9. doi: 10.1093/carcin/bgh038. Epub 2003 Dec 4. Carcinogenesis. 2004. PMID: 14656941

Cite

Share

4

Cite

Share

Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens.

Pulling LC, Vuillemenot BR, Hutt JA, Devereux TR, Belinsky SA. Pulling LC, et al. Among authors: vuillemenot br. Cancer Res. 2004 Jun 1;64(11):3844-8. doi: 10.1158/0008-5472.CAN-03-2119. Cancer Res. 2004. PMID: 15172992

Cite

Share

5

Cite

Share

Lymphoid tissue and emphysema in the lungs of transgenic mice inducibly expressing tumor necrosis factor-alpha.

Vuillemenot BR, Rodriguez JF, Hoyle GW. Vuillemenot BR, et al. Am J Respir Cell Mol Biol. 2004 Apr;30(4):438-48. doi: 10.1165/rcmb.2003-0062OC. Epub 2003 Sep 11. Am J Respir Cell Mol Biol. 2004. PMID: 12972399

Cite

Share

6

Cite

Share

Tralesinidase alfa enzyme replacement therapy prevents disease manifestations in a canine model of mucopolysaccharidosis type IIIB.

Ellinwood NM, Valentine BN, Hess AS, Jens JK, Snella EM, Jamil M, Hostetter SJ, Jeffery ND, Smith JD, Millman ST, Parsons RL, Butt MT, Chandra S, Egeland MT, Assis AB, Nelvagal HR, Cooper JD, Nestrasil I, Mueller BA, Labounek R, Paulson A, Prill H, Liu XY, Zhou H, Lawrence R, Crawford BE, Grover A, Cherala G, Melton AC, Cherukuri A, Vuillemenot BR, Wait JC, O'Neill CA, Pinkstaff J, Kovalchin J, Zanelli E, McCullagh E. Ellinwood NM, et al. Among authors: vuillemenot br. J Pharmacol Exp Ther. 2022 Jun 18:JPET-AR-2022-001119. doi: 10.1124/jpet.122.001119. Online ahead of print. J Pharmacol Exp Ther. 2022. PMID: 35717448 Free article.

Cite

Share

7

Cite

Share

Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease.

Hammon K, de Hart G, Vuillemenot BR, Kennedy D, Musson D, O'Neill CA, Katz ML, Henshaw JW. Hammon K, et al. Among authors: vuillemenot br. Clin Transl Sci. 2021 Sep;14(5):1810-1821. doi: 10.1111/cts.13028. Epub 2021 Jun 2. Clin Transl Sci. 2021. PMID: 34076336 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia.

Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, Dere RC, Carrasco-Triguero M, Lee MV, Saad OM, Liu L, He J, Su D, Xu K, Vuillemenot BR, Laing ST, Schutten M, Kozak KR, Zheng B, Polson AG, Kamath AV. Leipold DD, et al. Among authors: vuillemenot br. MAbs. 2018 Nov-Dec;10(8):1312-1321. doi: 10.1080/19420862.2018.1517565. Epub 2018 Oct 2. MAbs. 2018. PMID: 30183491 Free PMC article.

Cite

Share

9

Cite

Share

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG. Leong SR, et al. Among authors: vuillemenot br. Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1. Blood. 2017. PMID: 27908880 Free PMC article.

Cite

Share

10

Cite

Share

Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.

Vuillemenot BR, Korte S, Wright TL, Adams EL, Boyd RB, Butt MT. Vuillemenot BR, et al. Toxicol Sci. 2016 Jul;152(1):3-9. doi: 10.1093/toxsci/kfw072. Toxicol Sci. 2016. PMID: 27354708 Review.

Cite

Share